Skip to content

Study on the Clinical Efficacy of Optimized Qinggan Jieyu Decoction in Treating Liver Depression and Heat Syndrome

Study on the Clinical Efficacy of Optimized Qinggan Jieyu Decoction in Treating Liver Depression and Heat Syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021839
Enrollment
Unknown
Registered
2019-03-12
Start date
2019-03-12
Completion date
Unknown
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver depression heat syndrome

Interventions

migraine :Optimized Qinggan Jieyu Decoction
non-organic insomnia:Optimized Qinggan Jieyu Decoction
premenstrual syndrome:Optimized Qinggan Jieyu Decoction
nonalcoholic fatty liver disease:Optimized Qinggan Jieyu Decoction

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged 18-65 years, regardless of gender; (2) Patients who are in accordance with TCM syndrome differentiation for liver stagnation and heat syndrome; (3) Sign the informed consent form. (4) Comply with Western medicine for diagnosis of migraine or non-organic insomnia or premenstrual syndrome or nonalcoholic fatty liver disease;

Exclusion criteria

Exclusion criteria: (1) Those who have obvious syndromes or combined syndromes. (2) Those who are using other interventions are being treated. (3) Severe primary diseases such as heart, liver, brain, kidney and hematopoietic system, or mental patients. (4) Pregnancy or preparation for pregnancy, lactating women. (5) Those who are known to be allergic to this type of drug and have serious allergies. (6) Patients who participated in other clinical drug trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Liver stagnation heat syndrome syndrome evaluation scale;

Secondary

MeasureTime frame
Number of headache attacks and half the rate of seizures;Day of headache;Migraine based on patient-reported outcome rating scale;Pittsburgh sleep quality index;Symptom severity daily report;BMI;Aspartate aminotransferase, alanine aminotransferase, triglyceride, cholesterol, low density lipoprotein,;Hepatic B ultrasound;SF-36 Quality of Life Scale Chinese version;Norepinephrine,IL-6;

Countries

China

Contacts

Public ContactYing Gao
gaoying973@126.com+86 010 84013148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026